The Lymphoma Academic Research Organisation

This study tests whether a combination of two drugs, mosunetuzumab and lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has returned or not responded to prior therapy. About 260 adults who have had 1 to 3 prior treatments will be ran…

This study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or not responded to prior treatment. About 60 adults will take part to see if the combination can shrink tumors and how safe…

This study tests whether adding the experimental drug lacutamab to standard chemotherapy helps people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or stopped responding to previous treatments. About 56 adults whose cancer cells have a specific m…

This study reviews medical records from about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. Researchers want to see how well the drug controls the cancer and what side effects occur, especially in patients whose…

This study tests whether combining the drugs glofitamab, venetoclax, and zanubrutinib can help people with a fast-growing type of lymphoma called mantle-cell lymphoma. It includes 100 adults whose cancer has not responded to prior treatment or who have a very high-risk form of th…

This study is a registry that collects information from women who have a rare type of lymphoma (cancer) linked to breast implants. The goal is to better understand the disease, how it responds to treatment, and how to improve care. The registry is open in France and Belgium and w…

This study is a registry that collects information on up to 5,000 people with blood cancers who are eligible for CAR-T cell therapy. It looks at how long patients live, how well the treatment works, and how long it takes to start therapy. The goal is to learn from real-world expe…

This study is testing new drugs or drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The main goal is to gather early information on safety and effectiveness to help design better future studies. About 49 adults will ta…